Abstracts tagged "adalimumab and juvenile idiopathic arthritis-enthesitis (ERA)"

Abstract Number: 63 • 2017 Pediatric Rheumatology Symposium
Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
Rubén Burgos-Vargas¹, Gerd Horneff², Shirley M.L. Tse³, Pierre Quartier⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁶, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA), with clinical features similar to those of adult spondyloarthritis (SpA). An unmet ERA…
Abstract Number: 386 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Clinc Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…